Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In Focus

What the new PRAME data means for Immatics stock

Fresh clinical results for Immatics (NasdaqCM:IMTX) are in focus after updated Phase 1b IMA402 and Phase 1 IMA203CD8 data in PRAME expressing solid tumors were shared at the 2026 ESMO meeting.

The readout centers on heavily pretreated melanoma and ovarian cancer patients, where Immatics reported objective responses, disease control and durability signals, alongside what management described as manageable safety profiles for both programs.

Immatics shares trade at US$7.20 and the stock has had a weak run, with the 30 day share price return down 18%, the year-to-date share price return down 31.1%, and the 1-year total shareholder return down 29.34%.

Scan beyond Immatics and review additional hand picked oncology and biotech opportunities with 18 high quality undiscovered gems that are aligned to strong fundamentals and under the radar pipelines.

Fresh data and a sliding share price now pull in opposite directions for Immatics. After this drop, does the current valuation still skew the risk reward toward buyers, or has the market already priced the promise in?

Preferred price-to-sales of 21.1x: Is it justified for Immatics?

On current figures, Immatics screens as expensive on revenue based metrics, with a P/S ratio of 21.1x even after the share price slide to $7.20. That premium sits alongside a value score of 1, which flags that the stock screens as weak on traditional valuation checks.

The price to sales ratio compares a company's market value with its annual revenue, so a higher multiple means investors are paying more for each dollar of top line. For a clinical stage biotech like Immatics with no profits and a net loss of €206.549m, P/S often becomes the default yardstick because there are no earnings for a P/E ratio.

Against the US Biotechs industry average P/S of 11.6x, Immatics trades on a materially richer multiple. That indicates the market is assigning a higher value to its PRAME platform, pipeline and forecast revenue trajectory than to the typical peer, even though losses have increased at 19.9% per year over the past 5 years and the business is not expected to reach profitability in the next 3 years. At the same time, this 21.1x ratio screens as expensive versus an estimated fair P/S of 0x. This underlines how far expectations would need to moderate before the valuation moved closer to that fair ratio level.

Explore the SWS fair ratio for Immatics.

Result: Price-to-sales of 21.1x (OVERVALUED)

Still, the investment case around Immatics can quickly weaken if PRAME trial data underwhelms in later cohorts, or if ongoing net losses of €206.549m pressure funding options.